Arrhythmogenic right ventricular dysplasia: pregnancy under flecainide treatment.
This is the first reported case of a young woman with a moderate to severe form of arrhythmogenic right ventricular dysplasia under flecainide treatment who, with her physician's consent, decided to have a baby. During the pregnancy, antiarrhythmic drug therapy was continued and plasma levels of flecainide were measured via high-performance liquid chromatography. Every three months, she was monitored by means of resting ECG, signal-averaging ECG, 24-hour ECG and echocardiogram. We did not observe any meaningful events. A normal baby was delivered at full term by cesarean section. The baby's Apgar score was 9 after 1 and 5 minutes. The baby had to be fed using artificial milk. In conclusion, no changes in the pathology of the right ventricle were observed, we did not record any arrhythmia and the use of flecainide acetate did not cause any teratogenic effects. Nevertheless, we cannot assign any epidemiologic value to our report.
Villanova
C
C
Department of Internal Medicine, University of Padua.
Muriago
M
M
Nava
F
F
D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D019571:Arrhythmogenic Right Ventricular Dysplasia / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005424:Flecainide / Q000627:therapeutic use*; D006801:Humans; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000175:diagnosis / Q000188:drug therapy*; D011256:Pregnancy Outcome
D000889:Anti-Arrhythmia Agents; D005424:Flecainide